Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Development and validation of a clinical and genetic model for predicting risk of severe COVID-19

View ORCID ProfileGillian S. Dite, View ORCID ProfileNicholas M. Murphy, View ORCID ProfileRichard Allman
doi: https://doi.org/10.1101/2021.03.09.21253237
Gillian S. Dite
1Genetic Technologies Ltd., Fitzroy, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gillian S. Dite
  • For correspondence: gillian.dite@gtglabs.com
Nicholas M. Murphy
1Genetic Technologies Ltd., Fitzroy, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicholas M. Murphy
Richard Allman
1Genetic Technologies Ltd., Fitzroy, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Allman
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Clinical and genetic risk factors for severe COVID-19 are often considered independently and without knowledge of the magnitudes of their effects on risk. Using SARS-CoV-2 positive participants from the UK Biobank, we developed and validated a clinical and genetic model to predict risk of severe COVID-19. We used multivariable logistic regression on a 70% training dataset and used the remaining 30% for validation. We also validated a previously published prototype model. In the validation dataset, our new model was associated with severe COVID-19 (odds ratio per quintile of risk=1.77, 95% confidence interval [CI]=1.64, 1.90) and had excellent discrimination (area under the receiver operating characteristic curve=0.732, 95% CI=0.708, 0.756). We assessed calibration using logistic regression of the log odds of the risk score, and the new model showed no evidence of over- or under-estimation of risk (α=−0.08; 95% CI=−0.21, 0.05) and no evidence or over- or under-dispersion of risk (β=0.90, 95% CI=0.80, 1.00). Accurate prediction of individual risk is possible and will be important in regions where vaccines are not widely available or where people refuse or are disqualified from vaccination, especially given uncertainty about the extent of infection transmission among vaccinated people and the emergence of SARS-CoV-2 variants of concern.

Key results

  • Accurate prediction of the risk of severe COVID-19 can inform public heath interventions and empower individuals to make informed choices about their day-to-day activities.

  • Age and sex alone do not accurately predict risk of severe COVID-19.

  • Our clinical and genetic model to predict risk of severe COVID-19 performs extremely well in terms of discrimination and calibration.

Competing Interest Statement

GSD, NMM, and RA are employees of Genetic Technologies Limited. Genetic Technologies Limited had no role in the conceptualization, design, data analysis, decision to publish or preparation of the manuscript. Aspects of this manuscript are covered by Provisional Patent Application AU_2021900392 (pending), Methods of assessing risk of developing a severe response to Coronavirus infection. GSD, NMM, and RA are named inventors on the patent application, which is assigned to Genetic Technologies Limited.

Funding Statement

No external funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The UK Biobank has Research Tissue Bank approval (REC #11/NW/0382) that covers analysis of data by approved researchers. All participants provided written informed consent to the UK Biobank before data collection began. This research has been conducted using the UK Biobank resource under Application Number 47401.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • We have removed the validation analyses of the SNPs identified by Pairo-Castineira et al (Nature 2021; 591: 92-98) and have written these up as a separate analysis that we will also post on medRxiv.

Data Availability

We used data from the UK Biobank (under Application Number 47401) for these analyses and do not have permission to share the data. Researchers wishing to access the data used in this study can apply directly to the UK Biobank at https://www.ukbiobank.ac.uk/register-apply/.

https://www.ukbiobank.ac.uk/register-apply/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 28, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
Gillian S. Dite, Nicholas M. Murphy, Richard Allman
medRxiv 2021.03.09.21253237; doi: https://doi.org/10.1101/2021.03.09.21253237
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Development and validation of a clinical and genetic model for predicting risk of severe COVID-19
Gillian S. Dite, Nicholas M. Murphy, Richard Allman
medRxiv 2021.03.09.21253237; doi: https://doi.org/10.1101/2021.03.09.21253237

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1238)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10021)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1643)
  • Health Policy (752)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2280)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (536)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (157)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4833)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (491)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)